Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA

Journal of Thoracic Oncology

Volumn 7, Issue 9, 2012, Pages 1369-1381

  Nakamura, Tomomi ^a   Sueoka Aragane, Naoko ^a   Iwanaga, Kentaro ^a,b   Sato, Akemi ^a   Komiya, Kazutoshi ^a   Kobayashi, Naomi ^a   Hayashi, Shinichiro ^a   Hosomi, Toshiya ^c   Hirai, Mitsuharu ^c   Sueoka, Eisaburo ^d   Kimura, Shinya ^a  

^a SAGA UNIVERSITY   (Japan)

^b Saga Medical School   (Japan)

^c ARKRAY Healthcare Pvt Ltd   (Japan)

^d SAGA UNIVERSITY HOSPITAL   (Japan)

Author keywords

EGFR activating sensitive mutations; EGFR TKI; Lung cancer; Monitoring system; Plasma DNA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ISOLATION; EXON; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LUNG ADENOCARCINOMA; MALE; PRIORITY JOURNAL; QUENCHED PROBE SYSTEM; WILD INHIBITING POLYMERASE CHAIN REACTION;

EID: 84865697491     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31825f2821     Document Type: Article

References (33)

1. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237-2246. (Pubitemid 46621858)
2. Pérez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247. (Pubitemid 41103678)
3. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003;290:2149-2158. (Pubitemid 37432975)
4. Rosell R, Moran T, Queralt C, et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
6. Mitsudomi T, Morita S, Yatabe Y, et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
7. Maemondo M, Inoue A, Kobayashi K, et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-2388.
8. Pao W Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007;13:4954-4955. (Pubitemid 47502057)
9. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T, Mitsudomi T. A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 2006;8:335-341. (Pubitemid 44063810)
10. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-7282. (Pubitemid 41161259)
11. Matsumoto N, Kakihara F, Kimura S, et al. Single nucleotide polymorphism genotyping of CYP2C19 using a new automated system. Anal Biochem 2007;370:121-123. (Pubitemid 47404484)
12. Tanaka R, Kuroda J, Stevenson W, et al. Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res 2008;32:1462-1467.
13. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792. (Pubitemid 40271173)
14. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
15. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764-5769. (Pubitemid 44629607)
16. Engelman JA Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14:2895-2899.
17. Nakamura T, Sueoka-Aragane N, Iwanaga K, et al. A non-invasive system for monitoring resistance to EGFR tyrosine kinase inhibitors with plasma DNA. J Thoracic Oncol In press.
18. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500. (Pubitemid 38720929)
19. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311. (Pubitemid 39209661)
20. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
21. Nakatomi K, Soda H, Kitazaki T, et al. Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib. Lung Cancer 2006;52:253-255.
22. Kaira K, Takahashi T, Murakami H, et al. Long-term survivors of more than 5 years in advanced non-small cell lung cancer. Lung Cancer 2010;67:120-123.
23. Sobin L, Wittekind CH. TNM Classification of Malignant Tumours, 6th Ed. New York, Wiley-Liss, 2002. Pp.99-103.
24. Uhara M, Matsuda K, Taira C, Higuchi Y, Okumura N, Yamauchi K. Simple polymerase chain reaction for the detection of mutations and deletions in the epidermal growth factor receptor gene: applications of this method for the diagnosis of non-small-cell lung cancer. Clin Chim Acta 2009;401:68-72.
25. Sueoka N, Sato A, Eguchi H, et al. Mutation profile of EGFR gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. J Cancer Res Clin Oncol 2007;133:93-102. (Pubitemid 44950241)
26. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001;313:139-142. (Pubitemid 33016703)
27. Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007;635:105-117. (Pubitemid 46756399)
28. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006;20:1496-1510. (Pubitemid 43830656)
29. Lecomte T, Berger A, Zinzindohoué F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002;100:542-548. (Pubitemid 34816154)
30. Lee YJ, Yoon KA, Han JY, et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res 2011;17:5179-5187.
31. Hibi K, Taguchi M, Nakayama H, et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin Cancer Res 2001;7:3135-3138. (Pubitemid 32963835)
32. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001;61:4675-4678. (Pubitemid 32691874)
33. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-990.